Infectious Diseases in Obstetrics and Gynecology

Infectious Diseases in Obstetrics and Gynecology / 2012 / Article

Research Article | Open Access

Volume 2012 |Article ID 543916 | 9 pages |

Progress towards Elimination of HIV Mother-to-Child Transmission in the Dominican Republic from 1999 to 2011

Academic Editor: Carmen Zorrilla
Received06 Jul 2012
Accepted16 Sep 2012
Published29 Nov 2012


In 1999, prevention of mother-to-child transmission (pMTCT) using antiretrovirals was introduced in the Dominican Republic (DR). Highly active antiretroviral therapy (HAART) was introduced for immunosuppressed persons in 2004 and for pMTCT in 2008. To assess progress towards MTCT elimination, data from requisitions for HIV nucleic acid amplification tests for diagnosis of HIV infection in perinatally exposed infants born in the DR from 1999 to 2011 were analyzed. The MTCT rate was 142/1,274 (11.1%) in 1999–2008 and 12/302 (4.0%) in 2009–2011 ( ), with a rate of 154/1,576 (9.8%) for both periods combined. This decline was associated with significant increases in the proportions of women who received prenatal HAART (from 12.3% to 67.9%) and infants who received exclusive formula feeding (from 76.3% to 86.1%) and declines in proportions of women who received no prenatal antiretrovirals (from 31.9% to 12.2%) or received only single-dose nevirapine (from 39.5% to 19.5%). In 2007, over 95% of DR pregnant women received prenatal care, HIV testing, and professionally attended delivery. However, only 58% of women in underserved sugarcane plantation communities (2007) and 76% in HIV sentinel surveillance hospitals (2003–2005) received their HIV test results. HIV-MTCT elimination is feasible but persistent lack of access to critical pMTCT measures must be addressed.

1. Introduction

HIV mother-to-child transmission (MTCT) continues to threaten child survival worldwide. Over two million children are infected with HIV, the vast majority infected by MTCT in low- and middle-income (LMI) countries [1, 2]. The persistence of HIV MTCT underscores the importance of increasing access to effective prevention of MTCT (pMTCT) strategies. Virtual elimination of HIV MTCT has been achieved in most industrialized countries, with declines of over 80%–90% in the number of cases of perinatally acquired HIV infection, and MTCT rates of under 2%-3% [35]. The use of highly active antiretroviral therapy ([HAART], defined as a regimen of three or more antiretrovirals from two or more classes), which is essential for elimination of MTCT and contributes to maternal health, has been shown to be cost effective compared to single-dose nevirapine in several LMI countries, including the Dominican Republic (DR) [68], but few data exist on the scalability of these measures or the current obstacles to eliminating MTCT in these countries [913].

The DR is home to 25% of persons living with HIV in the Caribbean, the second highest HIV-prevalence region in the world [1, 9, 10]. To assess progress towards MTCT elimination in this MI country, we analyzed data recorded at the time of collection of samples for virologic testing performed to determine whether perinatally exposed infants and young children had acquired HIV infection.

2. Methods

2.1. Population

Guardians of infants and children known or suspected of being perinatally HIV-exposed were asked if they would consent to diagnostic virologic testing of their children as part of pediatric care. The population tested included infants and children whose mothers were diagnosed with HIV infection before or during pregnancy, at delivery, and up to 25 months after the child’s birth. Since HIV infection is a frequent cause of death among Caribbean women of reproductive age [10], HIV antibody testing was performed in orphaned and abandoned minors if maternal serostatus was unavailable. If the patient was seropositive, his/her guardian was offered virologic testing. A case of HIV infection acquired by MTCT was defined as an infant with a positive HIV nucleic acid amplification test [11]. Infants who had negative HIV nucleic acid amplification tests and had no symptoms of HIV infection were considered uninfected, but were followed until their HIV antibody tests were negative.

2.2. Prenatal and Infant pMTCT Practices

From 1999–2004, in La Romana province, in the region that formerly had the highest HIV prevalence in 2002 [12], nongovernmental organizations provided prenatal, perinatal and neonatal multidose zidovudine-containing regimens, with elective cesarean delivery and exclusive formula feeding, to HIV-infected mothers and their infants [6, 13]. During this time period, all data for this paper were collected from La Romana (Figure 1). Outside of La Romana, most HIV-infected women who were diagnosed during pregnancy were offered single-dose nevirapine at delivery, and exclusive formula feeding for their infants, according to national guidelines [17]. From 2004–2008, some women diagnosed with HIV infection before or during pregnancy started or continued HAART if they needed it for immunodeficiency; others received single-dose nevirapine or a zidovudine-containing multidose regimen [13]. In 2008, the DR ministry of health issued guidelines recommending maternal HAART for pMTCT, whether or not the mother had evidence of immunodeficiency (Protocol for use of combined antiretroviral therapy in pregnant women living with HIV/AIDS, Ministry of Health, Santo Domingo, DR, October 2008). These guidelines called for initiating zidovudine and lamivudine combined with nevirapine if the woman’s CD4+ T-lymphocyte count was less than 250 cells per mm3 [18] or ritonavir-boosted lopinavir if the woman’s CD4+ T-lymphocyte count was higher. HAART users with a documented quantitative HIV RNA concentration (“viral load”) less than 1,000 viral particles/ml3 were advised to deliver vaginally; non-HAART users and those with unknown or higher viral loads were encouraged to undergo elective cesarean delivery.

2.3. Laboratory Testing

Plasma specimens were obtained at age one to 25 months from known perinatally exposed and/or HIV-antibody-positive infants born from 1999–2005 for DNA polymerase chain reaction (PCR) qualitative or quantitative HIV-1 “viral load” testing. If viral nucleic acid was detected, testing was repeated. If the result was negative and the sample had been obtained prior to six months of age, the test was repeated at age of six months. From 2006–2011, dried blood spots (DBS) obtained from perinatally exposed and/or HIV-antibody-positive infants and children aged one to 25 months were collected according to previously published procedures and tested for viral nucleic acid [19].

2.4. Data Abstraction, Processing and Analysis

Information regarding maternal HIV diagnosis, prenatal antiretroviral treatment, delivery, and infant antiretroviral treatment and nutrition was obtained from maternal and infant medical records from 1999 to 2005. Physicians and nurses providing care for perinatally HIV-exposed infants queried the parents or guardians about this information 2006–2011 and documented their responses on laboratory requisition forms for HIV PCR testing on DBSs when the parent or guardian consented to the infant’s HIV PCR test. No attempts were made to verify the data obtained, beyond reviewing maternal or infant records, if available. When guardians did not have the information, and it was not found in requisitions or records, values were coded as missing.

Data were entered into Excel databases, (one in La Romana, and the other for the rest of the sites) and updated with the DBS HIV test results when they were received. In 2012, the Excel databases were converted to Epi Info v3.5.1 for Windows (Centers for Disease Control and Prevention, 2008) files, the variables were harmonized, and the databases were merged and analyzed [20].

HIV MTCT rates per 100 infants and children were calculated for maternal and infant antiretroviral regimen, delivery and infant nutrition characteristics, year and period (pre- and post-HAART for pMTCT guidelines) of birth, and by the various pMTCT strategies. Chi-square or Fisher’s exact two-tailed tests were used to evaluate categorical variables for statistical significance. The Kruskal-Wallis test for two groups was used for continuous variables. Stratified analyses were performed to control for confounding.

2.5. Prenatal and Infant Feeding Practices

Proportions of women who attended prenatal care, had hospital deliveries and breastfed were obtained from 2007 Demographic and Health Survey (DHS) data [12]. Data on HIV in bateyes (underserved sugarcane plantation communities) were obtained from a DHS 2007 component [15]. Updates on pMTCT strategies in 2003–2005, 2009, and HIV prevalence estimates, projections, and national prevention objectives in 2009 were reviewed [14, 16, 21].

3. Results

3.1. Population

Data from 1,576 infants and children born from December 1, 1999 to December 31, 2011 were analyzed. These included data collected in 34 centers from 1,274 infants born from 1999–2008, and in 18 centers from 302 infants born from January 1, 2009 to December 31, 2011 (Figure 1). Age at specimen collection ranged from 20 days to 25 months (median = 3.0 months; mean = 4.7; s.d. = 3.9; mode = 2.0 months); 1,541 (97.8%) samples were collected before the child was 15 months old.

3.2. Prenatal, Delivery, and Postpartum pMTCT Practices

From 1999 to 2008, HIV infection was diagnosed during the pregnancy in 48.4% mothers, prior to the pregnancy in 21.7%, and during labor or within 72 hours of birth in 5.7% and 5.2%, respectively (Table 1). Maternal HIV infection was diagnosed after 72 hours and during the child’s infancy or early childhood in 12.6%. In 6.3%, testing was performed and maternal HIV infection was diagnosed at other or unknown times. After publication of the national guidelines recommending HAART for pMTCT (2009–2011), the proportion diagnosed during labor and delivery rose and the proportions diagnosed within 72 hours of birth and at other or unknown times declined significantly. Otherwise, the distribution did not change significantly from the 1999 to 2008 period.

Diagnosis and management1999–20082009–2011
No. (%)No. (%)
N = 1,274N = 302

Time of HIV diagnosis
 Before pregnancy277 (21.7)77 (25.5)
 During pregnancy617 (48.4)143 (47.4)
 Labor/delivery73 (5.7)38 (12.6)*
 ≤72 hours post-partum66 (5.2)5 (1.7)*
 After 72 hours160 (12.6)38 (12.6)
 Unknown81 (6.3)1 (0.3)*

Maternal antiretroviral use
 Any868 (68.1)265 (87.7)*
  HAART, either157 (12.3)205 (67.9)*
   AZT + 3TC + NVP1157 (12.3)59 (19.5)
   AZT-3TC-Lop2146 (48.3)*
  Multidose AZT19 (1.5)0
  Multidose AZT + 3TC61 (4.8)
  Single dose NVP3503 (39.5)60 (19.5)*
 Received no ARVs406 (31.9)37 (12.2)*
 Unknown121 (9.5)0*

Type of delivery
 Vaginal285 (22.4)81 (26.8)
 All Caesareans882 (69.2)199 (65.9)
  Elective caesarian882 (69.2)152 (50.3)
  Emergency caesarean 47 (15.6)
 Unknown107 (8.4)22 (7.3)

Infant nutrition
 Formula only972 (76.3)260 (86.1)*
 Breast feeding only67 (5.3)4 (1.3)*
 Both43 (3.4)13 (4.2)
 Unknown192 (15.1)25 (8.3)*

Infant antiretrovirals (ARVs)
 Started between 8–72 hours782 (61.4)184 (60.9)
  Multidose AZT81 (6.4)126 (41.7)*
  Single-dose NVP only701 (55.0) 58 (19.3)*
 Did not receive ARVs219 (17.2)74 (24.6)*
 Unknown273 (21.4)44 (14.5)*

* P < .01 by time period.
1Zidovudine, lamivudine, nevirapine highly active antiretroviral therapy.
2Zidovudine, lamivudine, ritonavir-boosted lopinavir highly active antiretroviral therapy.

Maternal antiretroviral use during pregnancy, labor, or delivery rose significantly (Table 1). Women in the earlier period were significantly more likely to receive a single-dose nevirapine regimen than women who delivered from 2009 to 2011. Conversely, women who delivered from 2009 to 2011 were significantly more likely to receive HAART than in 1999 to 2008. All 157 women who received HAART before 2009 had CD4+ T-lymphocyte counts less than 250 per mm3. The majority (57.6%) of women who delivered in 2009–2011 received HAART, and most of these HAART recipients had CD4 counts higher than 250 and received ritonavir-boosted lopinavir. Duration of nevirapine-containing HAART at delivery (median = 286 days) was longer than the duration of lopinavir-containing HAART (median = 104 days; ); mothers who used nevirapine-containing HAART were more likely to have started it before pregnancy than those who used lopinavir-containing HAART. Use of other multidose non-HAART regimens for one to 24 weeks was reported in 61 women who received combined zidovudine-lamivudine and 19 who received zidovudine during the pregnancy and caesarean delivery in the period 1999–2008; no multi-dose antiretroviral regimens other than HAART were reported in 2009–2011 (Table 1).

Over 60% of infants in both periods were delivered by caesarean section and were administered antiretrovirals between 8 and 72 hours after birth; these proportions did not vary significantly by period (Table 1). A single dose of nevirapine was administered to most infants who received antiretrovirals from 1999 to 2008, while most infants in the 2009–2011 period who received antiretrovirals received a multidose regimen ( ). The proportion who were exclusively formula-fed rose and the proportion who were exclusively breastfed declined significantly.

3.3. Perinatally Acquired HIV Infection

Overall, in both periods combined, HIV infection was diagnosed in 154/1,576 (9.8%) of perinatally exposed infants and children. The proportion infected declined from 11.1% (142/1,274) in 1999–2008 to 4.0% (12/302) in 2009–2011 ( ) (Table 2). MTCT varied in both periods by whether or not mothers received any antiretrovirals during pregnancy or delivery, and by type of antiretroviral regimen. MTCT rates were similar for infants whose mothers received single-dose nevirapine, regardless of when the nevirapine was given in 1999–2008. The MTCT rate in infants whose mothers received single-dose nevirapine was higher than in those whose mothers received prenatal HAART in 1999–2008 and in 2009–2011 (6.4% versus 2.5% and 5.7% versus 2.9%, resp.) (Table 2). However, the difference was only statistically significant when the two periods were combined; 9/331 [2.7%]) infants of mothers who received HAART were infected, versus 35/601 (5.8%) infants of mothers who received single-dose nevirapine ( ).

All perinatally exposed142/1,274 (11.1%)12/302 (4.0%)*
 Any maternal antiretrovirals54/861 (6.3)10/267 (3.7)
  HAART1 all4/157 (2.5)5/174 (2.9)
   AZT + 3TC + NVP24/157 (2.5)0/59
   AZT + 3TC + Lopinavir/r3 5/115 (4.3)
  Non-HAART multidose 4/80 (5.0)
  AZT-containing regimen
  Single-dose NVP ALL32/506 (6.3)3/60 (5.0)
   8 hours precaesarean25/395 (6.3)0/2
   Labor onset5/78 (6.4)
   At delivery2/30 (6.7)
   Unspecified 3/58 (5.2)
  Unknown14/211 (11.6) 2/30 (6.7)
 None 88/413 (21.3) 2/35 (5.7)*

 Vaginal68/285 (23.9)6/80 (7.5)*
 Caesarean60/882 (6.8) 5/199 (2.5)*
 Unknown14/107 (13.1)1/23 (4.3)*

Infant antiretrovirals
 Single-dose Nevirapine (SD NVP)48/782 (6.1)1/41 (2.4)
 SD-NVP after 72 hours1/13 (7.6)
 Zidovudine for six weeks7/139 (5.0)7/126 (5.6)
 Unknown/other/none32/340 (9.4)4/135 (3.0)

Infant feeding
 Breast fed only25/67 (37.3)0/2
 Mixed16/43 (37.2)0/4
 Formula only79/972 (8.1) 11/271 (4.1)*
 Unknown22/192 (11.5) 1/25 (4.0)*

* P < .05, comparison by time period, 1999–2008 versus 2009–2011.
P < .01 within period, by strategy.
1Highly active antiretroviral therapy.
2AZT-3TC-NVP: zidovudine, lamivudine, nevirapine.
3AZT-3TC-Lop/r: zidovudine, lamivudine, lopinavir (ritonavir boosted).

The MTCT rate among infants of mothers who received HAART varied significantly by how long the mother had received HAART at delivery. HAART duration was shorter (median = 16.5 days) in mothers whose infants were infected than in mothers whose infants were not infected (median = 161 days; ). In the 1999–2008 period, MTCT rates varied considerably by type of delivery, ranging from 6.8% with cesarean delivery to 23.9% with vaginal delivery. MTCT rates in the latter period were lower for both types of delivery (2.5% and 7.5% in infants delivered by cesarean and vaginally, resp.). MTCT rates also were higher and tended to vary more by infant-feeding strategy in 1999–2008 than in 2009–2011.

MTCT rates varied from 5.0% and 6.1% among infants receiving six weeks of zidovudine or single-dose nevirapine within 72 hours of birth, respectively, to 9.4% among infants who did not receive any antiretroviral in 1999–2008 (Table 2). In contrast, in 2009–2011, when most infants received antiretrovirals, MTCT rates ranged from 2.4% to 5.6% among infants receiving single-dose nevirapine or six weeks of zidovudine, and the differences were not significant. MTCT rates varied significantly in 1999–2008 from 8.1% in exclusively formula-fed infants to 37.3% in exclusively breastfed infants. In the latter periods, only 6 infants received breast milk; MTCT rate in those who were exclusively formula fed or receiving unknown nutrition was 4.1% and 4.0%, significantly lower than in 1999–2008. When the analysis was confined to infants whose mothers had received HAART, were delivered by cesarean and had exclusive formula feeding, the MTCT rate was 1.6% in 1999–2008 and 2.3% in 2009–2011. Only 1 of 81 infants born in La Romana in 2011 (1.2%) was infected.

MTCT rates varied significantly by center (Table 3); the MTCT rate in the La Romana center was lower than in other centers in both time periods, but the difference was only significant in 1999–2008 ( ). The decline in MTCT risk from 1999–2008 to 2009–2011 was from a higher baseline, of greater magnitude, and statistically significant at centers outside La Romana. The decline in the La Romana center was not statistically significant. When controlled for prenatal antiretroviral use and exclusive formula feeding, no differences in MTCT rates between La Romana and other centers were significant (Tables 2 and 3). Most of the declines in MTCT and the differences by center (Table 3) were due to higher use of maternal antiretrovirals and exclusive formula feeding in La Romana in 1999–2008, and higher use of maternal antiretrovirals and exclusive formula feeding in 2009–2011 in all centers.

MTCT rate MTCT rate
No. of infected/total (%)No. of infected/total (%)

La Romana20/301 (6.6) <.0018/212 (3.8).9
Other centers122/973 (12.5)4/90 (4.9)*

Any prenatal antiretroviral use
 La Romana6/179 (3.3).168/187 (4.3).8
 Other centers34/561 (6.1)2/78 (2.6)

Any prenatal antiretroviral use, formula only
 La Romana6/149 (4.0).288/183 (4.4).7
 Other centers35/547 (6.4)1/53 (1.9)

No prenatal antiretroviral use
 La Romana13/114 (11.4).0020/25 (0).036
 Other centers75/299 (25.1)2/12 (16.7)

No prenatal antiretroviral use, formula only
 La Romana4/31 (12.9).510/25 (0).15
 Other centers26/146 (17.8)2/10 (20)

*Difference between 1999–2008 period and 2009–2011 period P < .05.
3.4. Prenatal Screening, Delivery, and Infant Nutrition Practices in the DR

Prenatal care utilization in the DR was estimated at greater than 95% in 2007, and varied from 96.6% in Elias Piña to 99.6% in Santo Domingo and from 95.1% in women who had never attended school (uneducated) to 99.6% among high school graduates [13]. Almost all births (97.8%) of births were attended by a health professional, ranging from 84% in Elias Piña to 99.7% in Santo Domingo, and from 91.0% to 99.7% among uneducated and high school graduates, respectively. The vast majority (97.5%) of births occurred in hospitals (ranging from 83.3% to 99.1% in Elias Piña and Santo Domingo, and from 89.2% to 98.7% among uneducated women and high school graduates, resp.). The mean number of prenatal visits was 6.6. Only 7.8% of infants aged 0–5 months were exclusively breastfed [13]. In 2003–2005, in a survey of sentinel sites, over 95% of women consented to HIV prenatal testing; only 76% received their test results [21]. In one of the largest DR centers, samples for rapid tests are collected, stored, and performed at the end of the day; the pregnant women were asked to return the next day or week for the results [14]. HIV prevalence in pregnant women varied with the highest prevalence in La Vega (8.4%), Mao (5.4%) and La Romana (3.2%) [16].

Residents of bateyes (generally underserved persons, many of Haitian origin), were surveyed [15]; 92% of women who had a recent pregnancy had been tested for HIV during the pregnancy, but only 58% received posttest counseling, including their test results. HIV prevalence among female residents in bateyes was higher (3.1%) than in the general female DR population (0.8%) and varied from 3.1% among 20–24 year olds to 4.9% among 30–34 year olds, and was highest (7.9%) among women aged 45–49 years old. HIV prevalence in DR women varied by educational attainment, from less than .3% in high school graduates to 3.7% in uneducated women [12, 16]. HIV prevalence in the general population varied geographically, with highest prevalence in the northernmost border with Haiti (1.6%) and the eastern sugar-growing region, where La Romana and most bateyes are located (1.2%), and the lowest prevalence in the middle-border region (.4%).

4. Discussion

The data in this study suggest that elimination of MTCT in the DR is feasible and attainable. Encouraging signs include the significant increases in proportion of women who received antiretrovirals during their pregnancy, with most of that increase being in HAART use in women without severe immunodeficiency, and the proportion of infants receiving exclusive formula feeding. These increases coincide with and largely explain the decrease in MTCT observed in the years since the publication of guidelines for use of HAART for pMTCT. They also coincide with some national trends that suggest a possible decline in HIV prevalence and unsafe sex practices, and documented increase in HAART use nationwide [1, 12, 16, 22, 23].

These encouraging findings contrast with persistent problems implementing the fundamentals of effective pMTCT, particularly informing pregnant women of their HIV status, and linking them to care and HAART. It is clear that all of the components of the “cascade” needed for MTCT elimination are present in the DR. These include high use of prenatal care and institutional delivery by trained personnel; high acceptability of prenatal HIV testing, formula feeding, and prenatal, perinatal, and infant antiretroviral use, and legislation that offers some protection, though modest and with draconian components, for people living with HIV [24, 25].

Yet the “weak links” in this system are unfortunately at points where they threaten the many strengths of the program. The principal weak links include the high proportion of women tested in prenatal care who do not receive their results. According to national guidelines, prenatal HIV testing in the DR is to be performed using rapid antibody tests; results of samples that test positive are then confirmed with another rapid test that uses a different principle, according to WHO guidelines [26], allowing infected pregnant women to receive at least presumptive, if not confirmed, positive test results in the same visit in which the sample for testing is obtained. Yet according to an observational study and a case report in some centers, samples were stored as they were collected and rapid tests run once a day; women were asked to return for their results, and posttest counseling sometimes consisted of reporting that the test “needs to be repeated” without clarifying that it was a presumptive positive test, leading to women delivering without an HIV diagnosis, MTCT, and maternal and infant HIV progression and death [14, 27, 28].

Another potential weakness in the cascade is the linkage to specialized care for an expedited CD4+ T-lymphocyte count to determine which HAART and other treatments are indicated for the mother’s health and pMTCT. In at least one center, in La Romana, this is facilitated by having the counselor (usually a woman living with HIV herself [21]), contact an HIV comprehensive care unit to have staff from that unit personally meet with and expedite the pregnant woman’s linkage to care. Models of this type in the DR have demonstrated the feasibility of effective linkage to care for pMTCT and maternal health. However, in centers whose referral process consists of asking the women to schedule an appointment with a specialized clinic, many women will not receive HAART, even if they continue prenatal care. Moreover, despite a high level of utilization of prenatal care and hospital delivery, the populations least likely to access these services include the most HIV-affected [12, 15]; alternative methods of reaching these populations are essential.

The dependence on ritonavir-boosted lopinavir (instead of efavirenz, as recommended by the WHO [29]) for HAART for women who are not severely immunesuppressed because of probably exaggerated concerns about its teratogenicity may limit their antiretroviral options in the future, and incurs a prohibitive cost compared to efavirenz [6]. Finally, although there is growing acceptance of the rights of people living with HIV, stigma, and discrimination continue to affect women with HIV in the DR [30, 31]. These women may also be unaware of their right to HAART at no cost [24, 25]. In the past, some HIV-infected women who did not receive their results found that they were given instead to employers, landlords or medical personnel; they were denied employment, housing, and elective medical services, including cesarean delivery for pMTCT [30, 31]. The new law criminalizes even protected sex with an uninfected partner; thus, some DR women who know or suspect their status may consider the risks of testing to be unacceptably high [24].

This study has several strengths. It contains data on by far the largest number of HIV perinatally exposed infants of any study conducted in the DR. A considerable amount of data was collected on infants from a large number of diverse centers distributed widely throughout the country. However, this analysis has several problems that limit its generalizability in characterizing MTCT in the DR. First, surveillance for perinatal HIV exposure that depends on testing living infants and children is susceptible to the important survival bias related to the high mortality (up to 30%) of untreated perinatally acquired HIV infection in the first two years of life [28]. Also, these data do not represent the majority of cases of perinatal exposure in the DR; the estimates of HIV prevalence in some DR pregnant and childbearing populations, and the numbers of HIV-infected women delivering each year (notably in La Romana and some sentinel surveillance hospitals) have been confirmed by several studies [13, 17], enabling reliable estimates of the proportion of perinatally exposed infants that are returned for virologic testing. At the national level, the estimated number of women with HIV who deliver annually (at least 1,400 to over 5,700) is much higher than the number of infants tested. This study represents at best a small proportion of DR perinatally exposed infants [6, 13, 16, 17, 21], and greatly over represents the centers (the NGO in La Romana and one of the public Maternity Hospitals in Santo Domingo) [14] with the best outcomes.

Despite these limitations, this analysis represents the first glimpse of the impact of the historic recommendations for HAART use for pMTCT with a large, representative database. It suggests that MTCT elimination is possible with current tools; indeed, some of the DR’s 2012 benchmarks were achieved in 2011 [16]. Barriers to elimination are related to failures to ensure that HIV-infected women are informed of their status and linked to care. Structural barriers limit healthcare access for the DR’s most HIV-affected, most marginalized populations. Surmounting these barriers requires innovative strategies to close the gaps in this promising model [32].


The authors gratefully acknowledge the contributions of José Ledesma, M.D., Ana Gloria Bido, M.D., and David Martin, M.D., of the Clinton Foundation HIV/AIDS Initiative, Santo Domingo, who supported all aspects of the use of dried blood spots for collection of specimens for virologic testing, in collaboration with the Dirección General de Control de Infecciones de Transmisión Sexual y SIDA; Susan A. Fiscus, Ph.D., Mark Turner, and the staff at the University of North Carolina Retrovirology Laboratory, Chapel Hill, North Carolina; the Virology Laboratory of the National Institute of Communicable Diseases in Johannesburg, South Africa, and the National Virology Laboratory for performing the virologic testing; the staff of the 20 participating HIV MTCT programs, including counselors, physicians, nursing, and laboratory staff; the mothers and guardians of the infants who consented to virologic testing and the peer-community-based home visitors and caregivers who promoted adherence to prenatal and infant antiretroviral and safe artificial formula use.


  1. Joint United Nations Programme on HIV/AIDS, UNAIDS World AIDS Day Report,, 2011.
  2. World Health Organization, “Progress report 2011: global HIV/AIDS response,” Tech. Rep., WHO, Geneva, Switzerland, 2011. View at: Google Scholar
  3. S. K. Whitmore, A. W. Taylor, L. Espinoza, R. L. Shouse, M. A. Lampe, and S. Nesheim, “Correlates of mother-to-child transmission of HIV in the United States and Puerto Rico,” Pediatrics, vol. 129, no. 1, pp. e74–e81, 2012. View at: Google Scholar
  4. C. L. Townsend, M. Cortina-Borja, C. S. Peckham, A. De Ruiter, H. Lyall, and P. A. Tookey, “Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006,” AIDS, vol. 22, no. 8, pp. 973–981, 2008. View at: Publisher Site | Google Scholar
  5. S. Tariq, C. L. Townsend, M. Cortina-Borja et al., “Use of zidovudine-sparing HAART in pregnant HIV-infected women in Europe: 2000–2009,” Journal of Acquired Immune Deficiency Syndromes, vol. 57, no. 4, pp. 326–333, 2011. View at: Publisher Site | Google Scholar
  6. N. C. Schmidt, J. Roman-Pouriet, A. D. Fernandez, C. M. Beck-Sagué, J. Leonardo-Guerrero, and S. W. Nicholas, “Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic,” International Journal of Gynecology & Obstetrics, vol. 116, no. 3, pp. 219–222, 2012. View at: Publisher Site | Google Scholar
  7. B. Robberstad and B. Evjen-Olsen, “Preventing mother to child transmission of HIV with highly active antiretroviral treatment in Tanzania-a prospective cost-effectiveness study,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 3, pp. 397–403, 2010. View at: Publisher Site | Google Scholar
  8. S. Orlando, M. C. Marazzi, S. Mancinelli et al., “Cost-effectiveness of using HAART in prevention of mother-to-child transmission in the DREAM-project Malawi,” Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 5, pp. 631–634, 2010. View at: Publisher Site | Google Scholar
  9. Joint United Nations Program on HIV/AIDS (UNAIDS) and World Health Organization (WHO), AIDS Epidemic Update 2009, World Health Organization, Geneva, Switzerland, 2009.
  10. United States Agency for International Development, HIV/AIDS Health profile for the Caribbean Region,, Pages 1–6, 2012.
  11. Centers for Disease Control and Prevention, “Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008,” Morbidity and Mortality Weekly Report, vol. 57, no. 10, pp. 5–8, 2008. View at: Google Scholar
  12. Centro de Estudios Sociales and Demográficos (CESDEM) y Macro International Inc, Encuesta Demográfica y de Salud 2007. (Demographic and Health Survey, 2007, CESDEM y Macro International Inc., Santo Domingo, República Dominicana, 2008.
  13. J. Román-Poueriet, A. D. Fernandez, C. M. Beck-Sagué et al., “HIV infection and prevention of mother-to-child transmission in childbearing women: La Romana, Dominican Republic, 2002–2006,” Revista Panamericana de Salud Publica/Pan American Journal of Public Health, vol. 26, no. 4, pp. 315–323, 2009. View at: Google Scholar
  14. M. Connolly, C. Bautista-Soriano, and A. Castro, “Utilización formulario de la Historia Clínica Perinatal y Neonatal CLAP/OPS-OMS. (Use of the Clinical Perinatal and Neonatal History Forms CLAP/PAHO-WHO) Publicación Bol.,” CENISMI, vol. 19, no. 3, pp. 17–23, 2009. View at: Google Scholar
  15. CESDEM and Macro International Inc., Encuesta Socioemográfica y sobre VIH/SIDA en los Bateyes Estatales de la República Dominicana 2007, CESDEM y Macro International Inc., Santo Domingo, Dominican Republic, 2008.
  16. Consejo Presidencial del SIDA (COPRESIDA), “Ministerio de Salud Pública y Asistencia Social Informe de estimaciones y proyecciones de prevalencia de carga de enfermedad año 2009,”, 2011. View at: Google Scholar
  17. E. Perez-Then, R. Peña, M. Tavarez-Rojas et al., “Preventing mother-to-child HIV transmission in a developing country: the Dominican Republic experience,” Journal of Acquired Immune Deficiency Syndromes, vol. 34, no. 5, pp. 506–511, 2003. View at: Publisher Site | Google Scholar
  18. K. V. Shepard, “Clarification of risk factors for severe, life-threatening and fatal hepatotoxicity with VIRAMUNE (nevirapine),” 2004, SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166533.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=website&utm_term=cd4 nevirapine&utm_content=1, 2012. View at: Google Scholar
  19. G. G. Sherman, G. Stevens, S. A. Jones, P. Horsfield, and W. S. Stevens, “Dried blood spots improve access to HIV diagnosis and care for infants in low-resource settings,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 5, pp. 615–617, 2005. View at: Publisher Site | Google Scholar
  20. A. G. Dean, K. M. Sullivan, and M. M. Soe, “Epi Info and OpenEpi in epidemiology and clinical medicine. Health applications of free software,”, 2012. View at: Google Scholar
  21. E. Perez-Then, C. Bautista Soriano, R. Espinal et al., Centro Nacional de Investigaciones de Salud Materno-Infantil (CENISMI). Consolidation of strategies for reduction of HIV MTCT in the Dominican Republic (CENISMI-Glaser Project). CENISMI, Santo Domingo, DR.
  22. P. Rojas, R. Malow, B. Ruffin, E. M. Rothe, and R. Rosenberg, “The HIV/AIDS epidemic in the Dominican Republic: key contributing factors,” Journal of the International Association of Physicians in AIDS Care, vol. 10, no. 5, pp. 306–315, 2011. View at: Publisher Site | Google Scholar
  23. D. T. Halperin, E. A. De Moya, E. Pérez-Then, G. Pappas, and J. M. Garcia Calleja, “Understanding the HIV epidemic in the Dominican Republic: a prevention success story in the Caribbean?” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 1, pp. S52–S59, 2009. View at: Publisher Site | Google Scholar
  24. L. Fernandez, Ley 135-11 VIH/SIDA, Promulgated by the President, Santo Domingo, Dominican Republic, 2011.
  25. F. A. Cuello Camilo , “Statement by H. E. Ambassador Frederico Alberto Cuello CamiloRepresentative of the Dominican Republic to the United Nations,” in Proceedings of the High Level Meeting of VIH/SIDA, 2012, View at: Google Scholar
  26. World Health Organization, Rapid HIV Tests. 2004. Guidelines for Use in HIV Testing and Counselling Services in Resource-Constrained Settings, WHO, Geneva, Switzerland.
  27. A. Koppel, J. Leonardo-Guerrero, S. Rives, N. Paniagua-Torres, C. Sparrow, and C. M. Beck-Sagué, “Immune reconstitution inflammatory syndrome due to Mycobacterium bovis bacillus Calmette-Guérin in infants receiving highly active antiretroviral therapy: a call for universal perinatal rapid HIV testing prior to administration of BCG immunization of neonates,” Journal of Tropical Pediatrics, vol. 56, no. 4, Article ID fmp115, pp. 280–283, 2009. View at: Publisher Site | Google Scholar
  28. M. J. Mayaux, M. Burgard, J. P. Teglas et al., “Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease,” Journal of the American Medical Association, vol. 275, no. 8, pp. 606–610, 1996. View at: Google Scholar
  29. World Health Organization, “Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for public health approaches,”, 2012. View at: Google Scholar
  30. Cáceres Ureña FI. República Dominicana. Estigma y discriminación en personas que viven con el VIH,, 2012.
  31. M. Møllmann, A Test of Inequality: Discrimination against women living with HIV in the Dominican Republic. Human Rights Watch,, 16, 2004.
  32. S. W. Nicholas, “Towards the elimination of pediatric HIV/AIDS in New York State,” Journal of Public Health Management and Practice, vol. 16, no. 6, pp. 509–511, 2010. View at: Publisher Site | Google Scholar

Copyright © 2012 Osvaldo Lorenzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

2893 Views | 805 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.